milrinone and sb 203580

milrinone has been researched along with sb 203580 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Mori, H; Node, K; Ogai, A; Ogita, H; Papst, PJ; Sakata, Y; Sanada, S; Shinozaki, Y; Takashima, S; Terada, N; Yamada, J1

Other Studies

2 other study(ies) available for milrinone and sb 203580

ArticleYear
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
    Circulation, 2001, Aug-07, Volume: 104, Issue:6

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-Dependent Protein Kinases; Cardiovascular Agents; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Dogs; Enzyme Inhibitors; Flavonoids; Hemodynamics; Imidazoles; Indoles; Isoquinolines; Maleimides; Milrinone; Mitogen-Activated Protein Kinases; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Protein Kinase C; Pyridines; Pyridones; Sulfonamides; Ventricular Fibrillation

2001